巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Immunic

IMUX
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Immunic - 延遲價格・最後更新於 23/01 21:59
最高位
--
最低位
--
開市價
--
前收市價
9.820
成交量(千)
--
成交額(百萬)
--
買入
--
賣出
--
每手股數
--
市值(百萬)
257.77
市盈率
--
息率
--
差價
--
52週高低
28.214 - 6.960
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Immunic
證券代碼
IMUX.US
所屬板塊
Biotechnology
公司業務
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which includes IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function.
發行量
26249439
公司總部
1200 Avenue of the Americas, Suite 200
公司網址
https:/www.imux.com
公司電郵
jessica.breu@immunic.de
公司電話
+1 332 255-9818
暫無內容

關於

Immunic(IMUX.US)所屬的行業板塊為Biotechnology。
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which includes IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function.
詳細公司背景可參考: https:/www.imux.com